Latest news and press releases about Genprex, Inc. (GNPX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer.
Price
| Price | $3.41 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.10 |
| EV / EBITDA | 0.85 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -163.13% |
| Return on Invested Capital | -107.08% |
| Return on Assets | -96.27% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BDRX · BIVI · CERO · CMMB · CNSP · GRI · INM
Explore sector: Healthcare · Biotechnology
More sections of GNPX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks